Search

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

76.83 1.63

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

73.6

Max

76.04

Belangrijke statistieken

By Trading Economics

Inkomsten

292M

150M

Verkoop

-75M

377M

K/W

Sectorgemiddelde

26.737

60.149

EPS

1.221

Winstmarge

39.832

Werknemers

423

EBITDA

-62M

220M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+7.93% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.4B

9B

Vorige openingsprijs

75.2

Vorige sluitingsprijs

76.83

Nieuwssentiment

By Acuity

8%

92%

5 / 342 Rangschikking in Healthcare

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 jul 2026, 23:52 UTC

Correlated Moves
Social Media
News

Western Digital shares fell after hours, closing at about $513.97. Option traders showed bearish sentiment, with puts outpacing calls in volume.

15 jul 2026, 23:26 UTC

News

Synopsys shares are higher in after-market hours following a Buy rating from analyst Gary Mobley, who set a price target of $570.

15 jul 2026, 23:16 UTC

Social Media
News

PayPal Holdings Inc. shares are lower in after-market trading amid uncertainty over a $53 billion acquisition offer from Stripe and Advent International.

15 jul 2026, 23:11 UTC

Correlated Moves
News

The CHF/HKD exchange rate is trading higher, influenced by a decline in the US Producer Price Index and a stronger NY Empire State Manufacturing Index.

15 jul 2026, 23:06 UTC

Social Media
News

Wedbush initiates coverage on eBay with an Outperform rating. Shares are higher in after-hours trading following positive sentiment and acquisition news.

15 jul 2026, 23:06 UTC

News

American Airlines Group shares are lower in after-market hours following the appointment of John W. Dietrich to its board amid rising fuel price concerns.

15 jul 2026, 23:06 UTC

News

Vanguard Total Bond Market ETF is slightly higher in after-market hours, reflecting cautious investor sentiment amid escalating Middle East tensions and oil supply concerns.

15 jul 2026, 23:02 UTC

News
Social Media
Event

United Airlines Holdings shares fell in after-hours trading despite reporting strong second-quarter earnings of $1.99 per share and revenue of $17.67 billion.

15 jul 2026, 23:01 UTC

Social Media
News

J.B. Hunt Transport Services shares rose in after-market trading following strong second-quarter results, with revenues up 19% to $3.50 billion and EPS of $1.91.

15 jul 2026, 23:01 UTC

News

Wedbush initiated coverage on Booking Holdings with an Outperform rating. Shares are higher in after-market trading following a close at $174.85.

15 jul 2026, 22:16 UTC

News

Micron Technology will participate in the KeyBanc Capital Markets Technology Leadership Forum on August 10, 2026. Shares are higher in after-hours trading.

15 jul 2026, 20:14 UTC

ETF Constituents
News
Correlated Moves

The Vanguard Large-Cap ETF is lower in after-market hours, influenced by slight declines in major holdings like Microsoft and Apple amid mixed U.S. equity performance.

15 jul 2026, 20:07 UTC

News

Bitcoin's price is declining amid broader market sentiment shifts following softer inflation readings. Geopolitical tensions may also be influencing the cryptocurrency market.

15 jul 2026, 20:07 UTC

News
Correlated Moves

Microchip Technology shares are lower today, following a broader Nasdaq decline. Ongoing U.S.-Iran tensions continue to affect overall investor sentiment.

15 jul 2026, 20:07 UTC

News

Ethereum is trading higher, continuing an upward trend since Tuesday. The U.S. Producer Price Index decline has eased inflation concerns and boosted market sentiment.

15 jul 2026, 20:07 UTC

News

Bitcoin's price is lower today, influenced by softer inflation data and ongoing geopolitical tensions, despite earlier gains above Tuesday's close.

15 jul 2026, 20:06 UTC

News

Charter Communications shares rose following Liberty Broadband's $17.65 million insider sale of 129,907 shares, despite a recent revenue decline.

15 jul 2026, 20:03 UTC

Social Media
News

Amazon.com Inc is higher today, driven by a partnership with Herotel for satellite internet services and leadership changes within Amazon Web Services.

15 jul 2026, 20:02 UTC

Social Media
News
Macro Event

CSX shares are lower as Benchmark cuts its price target to $4 from $48, while Citizens initiates coverage with a Market Perform rating.

15 jul 2026, 20:02 UTC

News

Cisco Systems Inc shares are lower, hitting a nine-week low of 111.29 USD amid a broader decline in the Communications Equipment sub-sector.

15 jul 2026, 20:02 UTC

News

Workday Inc. shares are higher, supported by positive sentiment after a drop in the U.S. Producer Price Index, easing inflation concerns and interest rate hike expectations.

15 jul 2026, 20:02 UTC

Social Media
News

Apple Inc. shares rose after regulatory approval for its generative AI service in China and Citibank's price target increase to $365 amid market challenges.

15 jul 2026, 20:02 UTC

Correlated Moves
News
Macro Event
Social Media

Lam Research shares are lower as the Semiconductor Materials & Equipment sector declines. UBS raised its price target to $435, despite negative sentiment from insider selling.

15 jul 2026, 20:02 UTC

Social Media
Macro Event
Event
News

Cintas Corp's stock rises following strong fiscal fourth-quarter results, with revenue of $2.91 billion and GAAP EPS of $1.26 exceeding analyst expectations.

15 jul 2026, 20:02 UTC

Correlated Moves
Social Media
Macro Event
News

Applied Materials Inc shares are lower today amid mixed assessments, despite UBS raising its price target to $705. The stock's recent surge raises investor caution.

15 jul 2026, 19:56 UTC

News
Social Media

Broadcom faces EU scrutiny over VMware practices, yet shares are higher amid positive sentiment for hardware makers and AI demand.

15 jul 2026, 19:56 UTC

News
Social Media

MercadoLibre shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential claims following extended loan term disclosures.

15 jul 2026, 19:56 UTC

News

Electronic Arts is rising amid reports of increased confidence in regulatory approval for its $55 billion acquisition at $210 per share.

15 jul 2026, 19:53 UTC

News
Social Media
Macro Event

Microsoft shares are higher today as Evercore ISI raised its price target to $525. Analysts remain optimistic ahead of the upcoming earnings report.

15 jul 2026, 19:52 UTC

News
Social Media

Alphabet Inc shares are higher, boosted by Warren Buffett's endorsement and plans for third-party stores in its App Store. Anticipation for earnings also supports momentum.

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

7.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 81 USD  7.93%

Hoogste 96 USD

Laagste 57 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

2

Hold

1

Sell

Sentiment

By Acuity

5 / 342 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
help-icon Live chat